We found that cGAS-STING scores were higher in the advanced-stage clinical subgroups in the METABRIC cohort, especially stage II and III&IV patients and patients with lymph node metastases (P < 0.001, Supplementary Fig. 3f, g). The gene discussed is CGAS; the disease is metastatic malignant neoplasm in the lymph nodes.